ArticleFrontiers in medicine2026
Identification of symptom clusters and associated factors based on disease characteristics in patients with esophageal cancer undergoing radiotherapy or chemoradiotherapy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify symptom clusters in patients with esophageal cancer undergoing radiotherapy or chemoradiotherapy, and to analyze their associated disease-related factors. Methods: A total of 289 patients receiving radiotherapy or chemoradiotherapy for esophageal cancer were recruited from the oncology departments of a tertiary general hospital in Nanjing between December 2021 and December 2023. Data were collected using a general information questionnaire and the esophageal cancer symptom assessment scale. Exploratory factor analysis and multiple linear regression were employed for statistical analysis. Results: The most prevalent symptoms were dysphagia (73.55%), fatigue (66.52%), weight loss (66.29%), sleep disturbance (62.58%), dry mouth (61.87%), shortness of breath (58.39%), nausea (57.42%), and pruritus (57.00%). Higher symptom incidence was associated with greater severity and distress. Four distinct symptom clusters were identified: psychosomatic, dysphagia, adverse reaction, and reflux-cough. Clinical stage, lesion location, and treatment modality emerged as independent predictors of symptom cluster severity ( Conclusion: Patients with esophageal cancer undergoing radiotherapy or chemoradiotherapy experience multiple concurrent symptoms that form identifiable clusters. Clinical nursing staff should prioritize the leading symptoms within each cluster and develop targeted interventions based on symptom severity and distress levels, thereby improving symptom management effectiveness and enhancing patients' quality of life during the treatment and recovery period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.